Cargando…

Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension

BACKGROUND: Pulmonary arterial hypertension (PAH) is associated with a substantial clinical and economic burden. Inhaled prostacyclins are a well-established part of pharmacotherapy for PAH. There are differences between inhaled therapies in the burden imposed by administration frequency. Simpler an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Charles D, Wu, Benjamin, Classi, Peter, Morland, Kellie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387966/ https://www.ncbi.nlm.nih.gov/pubmed/36580122 http://dx.doi.org/10.18553/jmcp.2023.29.1.101

Ejemplares similares

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Inhaled iloprost for the control of pulmonary hypertension
por: Krug, Sabine, et al.
Publicado: (2009)

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns
por: Yıldırım, Şükran
Publicado: (2023)

Review of inhaled iloprost for the control of pulmonary artery hypertension in children
por: Tissot, Cecile, et al.
Publicado: (2009)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Use of Inhaled Iloprost in an Infant With Bronchopulmonary Dysplasia and Pulmonary Artery Hypertension
por: Hwang, Seung-Kyung, et al.
Publicado: (2009)

Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension
por: Fernandes, Caio J.C.S., et al.
Publicado: (2021)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Acute hemodynamic effect of inhaled iloprost in pulmonary artery hypertension evaluated with echocardiography
por: Loureiro, Maria José, et al.
Publicado: (2007)

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
por: Richter, Manuel J., et al.
Publicado: (2018)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
por: Plaunt, Adam J., et al.
Publicado: (2021)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
por: Morland, Kellie, et al.
Publicado: (2021)

Inhaled Iloprost for Patients With Precapillary Pulmonary Hypertension and Right-Side Heart Failure
por: Martischnig, Amadea M., et al.
Publicado: (2011)

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016)

Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension
por: Wang, Lan, et al.
Publicado: (2017)

The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
por: Nakayama, Kazuhiko, et al.
Publicado: (2018)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
por: Mirza, Shireen, et al.
Publicado: (2012)

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Buckley, Mitchell S, et al.
Publicado: (2014)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Effects of inhaled iloprost on right ventriculovascular coupling and ventricular interdependence in acute pulmonary hypertension
por: Rex, S, et al.
Publicado: (2008)

Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates
por: Tavares‐Silva, Marta, et al.
Publicado: (2021)

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
por: Coons, James C., et al.
Publicado: (2021)

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
por: Zwicke, Diane L., et al.
Publicado: (2021)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Efficacy of Inhaled Iloprost in Cor Pulmonale and Severe Pulmonary Hypertension Associated with Tuberculous Destroyed Lung
por: Park, Yae Min, et al.
Publicado: (2014)

Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study
por: Richter, Manuel J., et al.
Publicado: (2019)

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension
por: Khan, Akram, et al.
Publicado: (2022)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
por: Spikes, Leslie A., et al.
Publicado: (2022)

Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP)
por: Stollfuss, Barbara, et al.
Publicado: (2021)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost
por: Channick, Richard N., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n1g36ts66mrhnd6mh687dua242